Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14280945 | 0.86 | — | — | |
| SCHEMBL13005171 | 0.79 | GRIN2D (0.31) | — | |
| SCHEMBL26080215 | 0.79 | PKM (0.39) | TSHR | |
| SCHEMBL25720236 | 0.75 | TRPA1 (0.31) | — | |
| SCHEMBL14409119 | 0.74 | ALDH1A1 (0.32) | HTTALDH1A1TSHR | |
| SCHEMBL9944701 | 0.73 | — | — | |
| SCHEMBL6188004 | 0.73 | CHRNB2 (0.38) | HSD11B1HTT | |
| SCHEMBL13005174 | 0.68 | CHRNB2 (0.39) | — | |
| SCHEMBL22604146 | 0.68 | — | — | |
| SCHEMBL21883665 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261999-A1 | Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261999-A1 | Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists | CHRNA1, CHRNA7, CHRNB1 | HSD11B1 1404/4885SCN1A 135/4885SCN2A 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.